Neuraxis, INC
About Neuraxis, INC
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.6M
- Net income
- -$7.8M
- Total assets
- $6.4M
- Market cap
- $84.7M
- Gross margin
- 84.2%
- Operating margin
- -219.4%
- Net margin
- -218.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.6M
- Cost of revenue
- $562.9K
- Gross profit
- $3.0M
- Operating expenses
- $10.8M
- Operating income
- -$7.8M
- Income tax
- -$2.0M
- Net income
- -$7.8M
- EPS (basic)
- $-0.95
- EPS (diluted)
- $-0.95
Balance sheet
- Total assets
- $6.4M
- Current assets
- $5.7M
- Total liabilities
- $3.0M
- Current liabilities
- $2.8M
- Shareholders’ equity
- $3.4M
Cash flow
- Operating cash flow
- -$6.4M
- Investing cash flow
- -$131.2K
- Financing cash flow
- $7.8M
- Net cash flow
- $1.3M
Statements via Polygon.io (SEC filings)
- Market cap
- $84.7M
- EPS (diluted)
- $-0.95
- Shares outstanding
- 12.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 9, 2023
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $7.8M in FY2025.
- Revenue grew 45% from FY2023 to FY2025.
- Gross margin of 84.2%, net margin -218.5%.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Neuraxis, INC.
Write a review
News about Neuraxis, INC
News & sentiment via Polygon.io
